Alset’s DSS Contingent Acquisition Depends on 2026 Note Conversion — Execution Uncertainty May Alter Ownership Structure

Overview of the Transaction Structure

This transaction represents a direct capital deployment, but its underlying structure is conditional. In December 2024, Alset reached an agreement to purchase 820,597 newly issued shares of DSS common stock for $800,000, equating to roughly $0.97 per share. This acquisition established Alset as the largest shareholder in DSS. However, the completion of this deal was not guaranteed; it was dependent on Alset successfully obtaining the necessary funding.

The financing requirement is directly linked to a previous arrangement. On August 20, 2025, DSS issued a $500,000 convertible promissory note to Alset Inc. This note, convertible into DSS common stock at $0.86 per share, served as the primary funding source for the stock purchase. The deal's conditional nature is clear: Alset's ability to finalize the $800,000 acquisition was contingent upon access to this $500,000 note, which itself originated from DSS.

The transaction was orchestrated by Heng Fai Chan, who chairs both Alset and DSS, and holds a substantial personal stake in DSS. This dual leadership and significant ownership suggest a high level of strategic alignment between the two companies. For institutional investors, this reduces concerns about conflicting interests, as the capital allocation reflects a unified decision by a closely connected leadership group.

Strategy Backtest: Absolute Momentum Long-Only

This strategy involves taking long positions in DSS when the 252-day rate of change is positive and the closing price exceeds the 200-day simple moving average (SMA). Exits occur if the price falls below the 200-day SMA, after 20 trading days, or if a take-profit (+8%) or stop-loss (−4%) threshold is reached. The backtest covers the past two years.

• Entry Criteria: 252-day rate of change > 0 and close > 200-day SMA
• Exit Criteria: Close < 200-day SMA, holding period >= 20 days, take-profit +8%, or stop-loss −4%
• Asset: DSS
• Risk Controls:
  • Take-Profit: 8%
  • Stop-Loss: 4%
  • Maximum Holding Period: 20 days

Backtest Performance

• Total Return: -56.06%
• Annualized Return: -33.75%
• Maximum Drawdown: 56.43%
• Profit-Loss Ratio: 1.1

Trade Statistics

• Total Trades: 17
• Winning Trades: 5
• Losing Trades: 12
• Win Rate: 29.41%
• Average Holding Period: 2.65 days
• Maximum Consecutive Losses: 8
• Average Gain per Win: 12.61%
• Average Loss per Trade: 10.65%
• Largest Single Gain: 15.69%
• Largest Single Loss: 32.37%

This approach of leveraging existing debt to finance equity purchases is a common tactic in companies with concentrated ownership or family control.

Financial Structure and Risk Considerations

The transaction relies on a tightly interlinked, conditional capital structure. At its core is a $500,000 convertible note that DSS issued to Alset Inc. in August 2025. This short-term debt, maturing on September 26, 2026, provides immediate liquidity to DSS but creates a near-term liability. The note’s conversion feature at $0.86 per share is pivotal, as it directly funds the $800,000 stock purchase. If fully converted, it would result in 581,395 new shares, significantly diluting existing shareholders.

The risk profile is straightforward: the deal is not finalized until Alset secures the required funding. Should Alset fail to complete the purchase, the $800,000 acquisition will not proceed, preserving DSS’s capital but signaling potential issues. Such a failure would likely be due to Alset’s inability to access the $500,000 note, which is itself a prior obligation from DSS. This creates a circular dependency, where DSS’s own financing is the prerequisite for a major shareholder’s investment, raising questions about the robustness of the capital allocation and the absence of external validation.

For institutional investors, this structure highlights a concentration of risk. The fixed conversion price of $0.86 determines the potential dilution, but the actual impact depends on whether the note is converted at face value or with accrued interest. This arrangement is typical in closely held firms, using debt to finance equity purchases and thus delaying dilution while maintaining control. The main takeaway is that while the financial structure appears sound, the execution risk is elevated due to its reliance on Alset’s ability to fund the purchase through the DSS note.

Portfolio Strategy and Sector Positioning

Alset’s investment in DSS is part of a broader strategy of consolidating capital within its portfolio. This transaction is not a standalone move but fits into a pattern of deepening stakes in related companies. Alset has previously committed $2.5 million in a convertible investment in DSS and provided $4.095 million via a secured note to HWH International. This preference for using convertible debt and secured notes to finance strategic acquisitions reflects a focus on capital efficiency and control. For institutional investors, this signals an emphasis on portfolio concentration and operational synergy, rather than broad diversification. The approach strengthens Alset’s influence over its portfolio companies, consistent with its role as both shareholder and potential acquirer.

For DSS, the capital impact is twofold. If the $500,000 note is not converted, the deal raises capital without diluting existing shareholders. However, if Alset chooses to convert the note at $0.86 per share, 581,395 new shares would be issued, diluting current shareholders and affecting earnings per share. The outcome depends entirely on Alset’s funding decision, making DSS’s capital structure reliant on Alset’s internal liquidity rather than its own financial health. This creates a scenario where DSS’s capital raise could simultaneously trigger dilution.

Importantly, this transaction does not signal a sector rotation. Alset’s investment is a targeted, strategic allocation within its existing network of controlled entities, reinforcing established relationships rather than shifting focus to new sectors. For portfolio managers, this is a company-specific event for DSS, not an indicator of broader sector trends. The capital flow remains internal, not a movement between different market segments.

Key Triggers, Risks, and Monitoring Points

The main event to watch is the September 26, 2026 maturity of the DSS convertible note. At this point, DSS must either repay the $500,000, renegotiate the terms, or allow Alset to convert the note into common stock at $0.86 per share. Conversion is the most probable outcome, as it would fund the $800,000 stock purchase and further consolidate Alset’s control. Any announcement regarding conversion would signal that the strategic transaction is advancing and that DSS’s capital structure is being reshaped to facilitate this internal capital allocation.

The central risk lies in the conditional nature of the arrangement. If Alset cannot secure the necessary funding, the deal collapses. This would not simply be a missed opportunity; it would publicly indicate a misalignment between a major shareholder and the company’s own financing strategy. For institutional investors, such an outcome could cast doubt on the strength of the capital allocation plan and suggest a lack of confidence from those in control. The circular dependency—where DSS’s own note is used to finance Alset’s purchase—means that execution risk is concentrated within the two entities and not mitigated by outside factors.

For investors, the monitoring strategy is clear: keep an eye out for any changes to the note’s terms or official announcements regarding conversion as the September 2026 maturity date approaches. These developments will determine whether the contingent capital allocation materializes, resulting in the issuance of 581,395 new shares and a shift in DSS’s ownership and capital structure. Until then, the transaction remains theoretical, with considerable execution risk.